Celldex Reports First Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Celldex Reports First Quarter 2015 Results
April 30, 2015 9:42 AM EDT
Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and $38 price target on Celldex Therapeutics (NASDAQ: CLDX) following in-line Q1 results and an pipeline update.
The analyst notes that at the end of the quarter, Celldex had $360 million in cash. "This seems sufficient to us to last into 2017, though could be impacted by the regulatory and commercialization plans for Rintega (rindopepimut),"... More
April 29, 2015 8:03 AM EDT
Celldex Therapeutics (NASDAQ: CLDX) reported Q1 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $406 thousand versus the consensus estimate of $460 thousand.
For earnings history and earnings-related data on (CLDX) click here.
...
More
